CLS vs. KNSA
CLS (Celestica Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. CLS operates in Electronic Components (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, CLS returned 106.30%/yr vs 37.13%/yr for KNSA. Their 0.15 correlation means their historical movements had little consistent relationship.
Performance
CLS vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLS achieves a 12.12% return, which is significantly lower than KNSA's 80.22% return.
CLS
- 1D
- -6.00%
- 1M
- -8.35%
- 6M
- 17.95%
- YTD
- 12.12%
- 1Y
- 65.84%
- 3Y*
- 149.34%
- 5Y*
- 106.30%
- 10Y*
- 40.47%
- ALL TIME*
- 13.58%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $1.16B | $852.74M | $822.47M | |
| $68.75M | $54.52M | $46.86M |
CLS vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 12.12% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -26.61% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between CLS and KNSA is 0.02, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.02 |
Correlation (3Y) Balances recent behavior with more history. | 0.13 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.16 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.15 |
The correlation between CLS and KNSA shifts across timeframes, from 0.02 (1 year) to 0.16 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
CLS:
$38.11B
KNSA:
$5.67B
CLS:
$9.64
KNSA:
$1.00
CLS:
34.38
KNSA:
74.38
CLS:
0.46
KNSA:
0.72
CLS:
2.46
KNSA:
7.14
CLS:
15.53
KNSA:
9.48
CLS:
$15.62B
KNSA:
$840.85M
CLS:
$1.81B
KNSA:
$546.22M
CLS:
$1.50B
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLS vs. KNSA — Risk / Return Rank
CLS
KNSA
CLS vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLS | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.06 | ||
| Sortino ratioReturn per unit of downside risk | -2.67 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.52 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.83 | 6.94 | -5.11 |
| Martin ratioReturn relative to average drawdown | 4.27 | 24.13 | -19.86 |
Loading charts...
Drawdowns
CLS vs. KNSA - Drawdown Comparison
The maximum CLS drawdown since its inception was -96.93%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for CLS and KNSA.
Loading charts...
Drawdown Indicators
| CLS | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.93% | -83.06% | -13.87% |
Max Drawdown (1Y)Largest decline over 1 year | -36.21% | -21.12% | -15.09% |
Max Drawdown (3Y)Largest decline over 3 years | -53.96% | -34.14% | -19.82% |
Max Drawdown (5Y)Largest decline over 5 years | -53.96% | -53.17% | -0.79% |
Max Drawdown (10Y)Largest decline over 10 years | -80.60% | — | — |
Current DrawdownCurrent decline from peak | -29.84% | -8.13% | -21.71% |
Average DrawdownAverage peak-to-trough decline | -73.10% | -40.09% | -33.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.47% | 6.06% | +9.41% |
Volatility
CLS vs. KNSA - Volatility Comparison
Celestica Inc. (CLS) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have volatilities of 25.97% and 26.47%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLS | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 25.97% | 26.47% | -0.50% |
Volatility (6M)Calculated over the trailing 6-month period | 55.62% | 41.55% | +14.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 74.89% | 49.77% | +25.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 58.52% | 54.77% | +3.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 50.65% | 64.34% | -13.69% |
Dividends
CLS vs. KNSA - Dividend Comparison
Neither CLS nor KNSA has paid dividends to shareholders.
Financials
CLS vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Celestica Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLS vs. KNSA - Profitability Comparison
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Celestica Inc. reported a gross profit of 577.50M and revenue of 4.70B. Therefore, the gross margin over that period was 12.3%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Celestica Inc. reported an operating income of 458.30M and revenue of 4.70B, resulting in an operating margin of 9.8%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Celestica Inc. reported a net income of 368.80M and revenue of 4.70B, resulting in a net margin of 7.9%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
Frequently Asked Questions
CLS and KNSA have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (26.47%) compared to CLS (25.97%). In terms of maximum drawdown, CLS dropped -96.93% vs KNSA's -83.06%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 0.88), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLS and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer